Recent developments, including the May 2026 resignation of prior commissioner Marty Makary and the subsequent acting role of Kyle Diamantas, have kept the FDA commissioner selection process fluid amid ongoing White House interviews with candidates such as Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara. Trader sentiment reflects a fragmented field because no single contender has secured a decisive edge in vetting or alignment with priorities like regulatory modernization and agency leadership stability. Key differentiators include Overton's Domestic Policy Council experience versus Vacirca's oncology network leadership or Ferrara's Pentagon health background, alongside Senate confirmation dynamics and historical patterns of rapid executive branch nominations. Factors that could consolidate support include an imminent formal announcement, committee feedback, or shifts in administration focus before year-end deadlines.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于斯蒂芬·哈恩 <1%
凯尔·迪亚曼塔斯 <1%
萨拉·布伦纳 <1%
截至12月31日没有宣布 <1%
$33,305 交易量
$33,305 交易量
2026-12-30
凯尔·迪亚曼塔斯
1%
斯蒂芬·哈恩
1%
布雷特·吉鲁瓦尔
<1%
格蕾丝·格雷厄姆
<1%
萨拉·布伦纳
1%
截至12月31日没有宣布
<1%
斯蒂芬·哈恩 <1%
凯尔·迪亚曼塔斯 <1%
萨拉·布伦纳 <1%
截至12月31日没有宣布 <1%
$33,305 交易量
$33,305 交易量
2026-12-30
凯尔·迪亚曼塔斯
$6,786 交易量
1%
斯蒂芬·哈恩
$4,144 交易量
1%
布雷特·吉鲁瓦尔
$5,265 交易量
<1%
格蕾丝·格雷厄姆
$6,683 交易量
<1%
萨拉·布伦纳
$7,418 交易量
1%
截至12月31日没有宣布
$3,007 交易量
<1%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments, including the May 2026 resignation of prior commissioner Marty Makary and the subsequent acting role of Kyle Diamantas, have kept the FDA commissioner selection process fluid amid ongoing White House interviews with candidates such as Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara. Trader sentiment reflects a fragmented field because no single contender has secured a decisive edge in vetting or alignment with priorities like regulatory modernization and agency leadership stability. Key differentiators include Overton's Domestic Policy Council experience versus Vacirca's oncology network leadership or Ferrara's Pentagon health background, alongside Senate confirmation dynamics and historical patterns of rapid executive branch nominations. Factors that could consolidate support include an imminent formal announcement, committee feedback, or shifts in administration focus before year-end deadlines.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
市场开放时间： May 12, 2026, 7:59 PM ET
交易量
$33,305结束日期
2026-12-31市场开放时间
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent developments, including the May 2026 resignation of prior commissioner Marty Makary and the subsequent acting role of Kyle Diamantas, have kept the FDA commissioner selection process fluid amid ongoing White House interviews with candidates such as Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara. Trader sentiment reflects a fragmented field because no single contender has secured a decisive edge in vetting or alignment with priorities like regulatory modernization and agency leadership stability. Key differentiators include Overton's Domestic Policy Council experience versus Vacirca's oncology network leadership or Ferrara's Pentagon health background, alongside Senate confirmation dynamics and historical patterns of rapid executive branch nominations. Factors that could consolidate support include an imminent formal announcement, committee feedback, or shifts in administration focus before year-end deadlines.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
交易量
$33,305结束日期
2026-12-31市场开放时间
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Recent developments, including the May 2026 resignation of prior commissioner Marty Makary and the subsequent acting role of Kyle Diamantas, have kept the FDA commissioner selection process fluid amid ongoing White House interviews with candidates such as Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara. Trader sentiment reflects a fragmented field because no single contender has secured a decisive edge in vetting or alignment with priorities like regulatory modernization and agency leadership stability. Key differentiators include Overton's Domestic Policy Council experience versus Vacirca's oncology network leadership or Ferrara's Pentagon health background, alongside Senate confirmation dynamics and historical patterns of rapid executive branch nominations. Factors that could consolidate support include an imminent formal announcement, committee feedback, or shifts in administration focus before year-end deadlines.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题